Isofol Medical AB (OSTO:ISOFOL) EPS without NRI: kr-0.24 (TTM As of Mar. 2026)


OSTO:ISOFOL Isofol Medical AB OSTO:ISOFOL
30 GF Score
Price kr0.83
! 2 Warning Signs
View Full Analysis

What is Isofol Medical AB EPS without NRI?

Isofol Medical AB OSTO:ISOFOL +7.10% 30 EPS without NRI is kr-0.24 as of Mar. 2026. GuruFocus rates OSTO:ISOFOL with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 1,168 Biotechnology companies, Isofol Medical AB ranks better than 71.32% on this metric.

Isofol Medical AB's earnings per share without non-recurring items for the three months ended in Mar. 2026 was kr-0.05. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was kr-0.24.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 34.50% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 40.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Isofol Medical AB's EPS without NRI or its related term are showing as below:

OSTO:ISOFOL' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -26.8   Med: 14.3   Max: 57.7
Current: 34.5

During the past 11 years, Isofol Medical AB's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 57.70% per year. The lowest was -26.80% per year. And the median was 14.30% per year.

OSTO:ISOFOL's 3-Year EPS without NRI Growth Rate is ranked better than
71.32% of 1168 companies
in the Biotechnology industry
Industry Median: 16.4 vs OSTO:ISOFOL: 34.50

Isofol Medical AB's EPS (Diluted) for the three months ended in Mar. 2026 was kr-0.05. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was kr-0.24.

Isofol Medical AB's EPS (Basic) for the three months ended in Mar. 2026 was kr-0.05. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was kr-0.24.


Isofol Medical AB  (OSTO:ISOFOL) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Isofol Medical AB EPS without NRI Related Terms


Isofol Medical AB EPS without NRI Historical Data

* Premium members only.

The historical data trend for Isofol Medical AB's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Isofol Medical AB EPS without NRI Chart

Isofol Medical AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.42 -0.89 -0.20 -0.27 -0.25

Isofol Medical AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.08 -0.09 -0.05 -0.05 -0.05

OSTO:ISOFOL vs VRTX, REGN, ALNY: EPS without NRI Comparison

For the Biotechnology subindustry, Isofol Medical AB's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Isofol Medical AB PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Isofol Medical AB's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Isofol Medical AB's PE Ratio without NRI falls into.


OSTO:ISOFOL
30GF Score
Isofol Medical AB OSTO:ISOFOL
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Isofol Medical AB EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of kr-0.24 mean?
Isofol Medical AB (OSTO:ISOFOL) has a EPS without NRI of kr-0.24 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Isofol Medical AB and its competitors. According to the industry distribution chart, Isofol Medical AB ranks #335 out of 1168 companies in the Biotechnology industry, placing it in the top 28.7%.
Is Isofol Medical AB's EPS without NRI too high?
Isofol Medical AB's current EPS without NRI is kr-0.24. Based on the distribution chart, Isofol Medical AB ranks #335 out of 1168 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Isofol Medical AB has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Isofol Medical AB's EPS without NRI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Isofol Medical AB ranks #335 out of 1168 companies for EPS without NRI. This puts Isofol Medical AB in the upper half of its industry. The industry median EPS without NRI is 16.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.40, based on 1,168 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Isofol Medical AB and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Isofol Medical AB's current EPS without NRI is kr-0.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Isofol Medical AB stock overvalued right now?
Isofol Medical AB (OSTO:ISOFOL) has a current EPS without NRI of kr-0.24. The current EPS without NRI is kr-0.24. Isofol Medical AB's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Isofol Medical AB (OSTO:ISOFOL), the current EPS without NRI is kr-0.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Isofol Medical AB Business Description

Address Arvid Wallgrens Backe 20, Biotech Center, Gothenburg, SWE, SE-413 46
Isofol Medical AB is a pharmaceutical company. It is a manufacturer of folate-based therapies. The company's drug candidate Modufolin enhances the effect of the current chemotherapy treatment for patients treated for colorectal cancer. Its products are used to increase efficacy and reduce the side effects of antimetabolite cancer treatment.
30GF Score

Get the complete analysis for OSTO:ISOFOL

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.83
Price